NCT00726583已完成1 期
A Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- Determine the MTD of PX-866
研究概览
简要总结
This study is being conducted to determine the safety and maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.
详细描述
PX-866 is a targeted inhibitor of PI-3K. This study is being conducted to determine the maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of advanced solid tumor and has failed or is intolerant of standard therapy, or for whom standard therapy does not exist.
- •18 years of age or older.
- •ECOG performance status 0 to
- •Predicted life expectancy of at least 12 weeks.
- •Discontinued prior chemotherapy or other investigational agents for at least three weeks prior to receiving the first dose of study drug (six weeks for mitomycin C, nitrosureas,vaccines,or antibody therapy)and recovered from the toxic effects of the prior treatment (recovered to baseline or ≤grade 1 per Common Toxicity Criteria for Adverse Events (CTCAE)).
- •Discontinued any radiation therapy for at least four weeks and have recovered from all radiation-related toxicities (recovered to baseline or ≤CTCAE grade 1) prior to receiving the first dose of study drug. Palliative radiation of 10 fractions or less is permitted and a four week interval is not necessary (also allowed during therapy).
- •Adequate hematologic function as defined by the following: WBC count >3,000 cells/μL; platelets >100,000/μL; hemoglobin >9 g/dL (may be transfused to this level); ANC >1500 cells/μL.
- •Adequate hepatic function as defined by the following: bilirubin <1.5 mg/dL; aspartate aminotransaminase (AST/SGOT) & alanine aminotransferase (ALT/SGPT) <2.5 x ULN or <5 x ULN if due to metastatic disease.
- •Adequate renal function as defined by serum creatinine level <1.5 mg/dL.
排除标准
- •Any active infection at study entry.
- •Known diabetes or fasting blood glucose>160 mg/dL.
- •Known human immunodeficiency virus (HIV).
- •Any serious concomitant systemic disorders that in the opinion of the investigator would place the patient at excessive or unacceptable risk of toxicity.
- •Surgery within the four weeks prior to the first dose
- •Significant central nervous system (CNS) or psychiatric disorder(s) that preclude the ability of the patient to provide informed consent.
- •Known or suspected brain metastases that have not received adequate therapy or for which the patient requires treatment with steroids or anticonvulsants. In the case of previously treated brain metastases, a minimum four week interval between completion of radiation therapy and registration on study with radiologic evidence of stable or responding brain metastases is required. In the setting of previous CNS metastasectomy, adequate (minimum four week) recovery from surgery and/or radiation therapy should be documented.
- •Leptomeningeal brain metastases should be excluded regardless of whether the metastases have been treated or not.
- •History of seizures, non-healing wounds, or arterial thrombosis.
- •Unstable atrial or ventricular arrhythmias requiring control by medication; any cardiac ischemic event experienced within the preceding six months; prior history of congestive heart failure requiring therapy.
- •Breastfeeding or pregnant (confirmed by serum β-HCG within 10 days prior to the start of study treatment if applicable).
- •Total gastrectomy, partial bowel obstruction or any gastrointestinal condition that may interfere with absorption of the study medication.
- •Any condition that could jeopardize the safety of the patient and compliance with the protocol.
研究组 & 干预措施
Investigational Drug
Experimental
Dose Escalation
干预措施: PX-866 (Drug)
结局指标
主要结局
Determine the MTD of PX-866
时间窗: 28 days
Evaluate pharmacodynamic measures of the effects of PX-866 on the phosphatidylinositol-3 kinase (PI-3K) pathway and related tumor markers.
时间窗: 28 days
Determine the PK profile of PX-866.
时间窗: 28 days
Evaluate the safety profile of PX-866
时间窗: 28 days
次要结局
- Evaluate the anti-tumor activity of PX-866 in patients with advanced malignancies.(56 days)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Study of PX-866 and Vemurafenib in Patients With Advanced MelanomaAdvanced BRAF-mutant CancersNCT01616199Cascadian Therapeutics Inc.24
终止
1 期
Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid TumoursAdvanced Solid TumoursNCT01859351Heidelberg Pharma AG13
进行中（未招募）
1 期
Study of PYX-106 in Solid TumorsSolid TumorNCT05718557Pyxis Oncology, Inc47
已完成
1 期
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsPIK3CA MutationSolid Tumor, AdultHER2-negative Breast CancerUnresectable Solid TumorHormone Receptor Positive TumorBreast CancerMetastatic Breast CancerAdvanced Breast CancerNCT05759949Relay Therapeutics, Inc.41
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)Cancer, AdvancedNCT00750178Merck Sharp & Dohme LLC30